Quantification and modeling of tripartite CD2-, CD58FC chimera (alefacept)-, and CD16-mediated cell adhesion.
Alefacept is a chimeric protein combining CD58 immunoglobulin-like domain 1 with human IgG1 Fc. Alefacept mediates adhesion by bridging CD2 on T cells to activating Fc receptors on effector cells, but the equilibrium binding parameters have not been determined. Alefacept mediated T cell killing by N...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2007
|
| _version_ | 1797102084545314816 |
|---|---|
| author | Dustin, M Starr, T Coombs, D Majeau, G Meier, W Hochman, P Douglass, A Vale, R Goldstein, B Whitty, A |
| author_facet | Dustin, M Starr, T Coombs, D Majeau, G Meier, W Hochman, P Douglass, A Vale, R Goldstein, B Whitty, A |
| author_sort | Dustin, M |
| collection | OXFORD |
| description | Alefacept is a chimeric protein combining CD58 immunoglobulin-like domain 1 with human IgG1 Fc. Alefacept mediates adhesion by bridging CD2 on T cells to activating Fc receptors on effector cells, but the equilibrium binding parameters have not been determined. Alefacept mediated T cell killing by NK cells and adhesion between CD2- and CD16-expressing cells at an optimum concentration of 100 nM. We introduce novel measurements with supported planer bilayers, from which key two-dimensional and three-dimensional parameters can be determined by data fitting. Alefacept competitively inhibited cell bilayer adhesion mediated by the CD2-CD58 interaction. Alefacept mediated maximal adhesion of CD2(+) T cells to CD16B, an Fc receptor, in planar bilayers at 500 nM. A mechanistic model for alefacept-mediated cell-bilayer adhesion allowed fitting of the data and determination of two-dimensional binding parameters. These included the density of bonds in the adhesion area, which grew to maintain a consistent average bond density of 200 molecules/microm(2) and two-dimensional association constants of 3.1 and 630 microm(2) for bivalently and monovalently bound forms of alefacept, respectively. The maximum number of CD16 bound and the fit value of 4,350 CD2 per cell are much lower than the 40,000 CD2 per cell measured with anti-CD2 Fab. These results suggest that additional information is needed to correctly predict Alefacept-mediated bridge formation. |
| first_indexed | 2024-03-07T06:00:52Z |
| format | Journal article |
| id | oxford-uuid:ec227937-0afd-4e80-905c-05b62b493d5a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:00:52Z |
| publishDate | 2007 |
| record_format | dspace |
| spelling | oxford-uuid:ec227937-0afd-4e80-905c-05b62b493d5a2022-03-27T11:15:09ZQuantification and modeling of tripartite CD2-, CD58FC chimera (alefacept)-, and CD16-mediated cell adhesion.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ec227937-0afd-4e80-905c-05b62b493d5aEnglishSymplectic Elements at Oxford2007Dustin, MStarr, TCoombs, DMajeau, GMeier, WHochman, PDouglass, AVale, RGoldstein, BWhitty, AAlefacept is a chimeric protein combining CD58 immunoglobulin-like domain 1 with human IgG1 Fc. Alefacept mediates adhesion by bridging CD2 on T cells to activating Fc receptors on effector cells, but the equilibrium binding parameters have not been determined. Alefacept mediated T cell killing by NK cells and adhesion between CD2- and CD16-expressing cells at an optimum concentration of 100 nM. We introduce novel measurements with supported planer bilayers, from which key two-dimensional and three-dimensional parameters can be determined by data fitting. Alefacept competitively inhibited cell bilayer adhesion mediated by the CD2-CD58 interaction. Alefacept mediated maximal adhesion of CD2(+) T cells to CD16B, an Fc receptor, in planar bilayers at 500 nM. A mechanistic model for alefacept-mediated cell-bilayer adhesion allowed fitting of the data and determination of two-dimensional binding parameters. These included the density of bonds in the adhesion area, which grew to maintain a consistent average bond density of 200 molecules/microm(2) and two-dimensional association constants of 3.1 and 630 microm(2) for bivalently and monovalently bound forms of alefacept, respectively. The maximum number of CD16 bound and the fit value of 4,350 CD2 per cell are much lower than the 40,000 CD2 per cell measured with anti-CD2 Fab. These results suggest that additional information is needed to correctly predict Alefacept-mediated bridge formation. |
| spellingShingle | Dustin, M Starr, T Coombs, D Majeau, G Meier, W Hochman, P Douglass, A Vale, R Goldstein, B Whitty, A Quantification and modeling of tripartite CD2-, CD58FC chimera (alefacept)-, and CD16-mediated cell adhesion. |
| title | Quantification and modeling of tripartite CD2-, CD58FC chimera (alefacept)-, and CD16-mediated cell adhesion. |
| title_full | Quantification and modeling of tripartite CD2-, CD58FC chimera (alefacept)-, and CD16-mediated cell adhesion. |
| title_fullStr | Quantification and modeling of tripartite CD2-, CD58FC chimera (alefacept)-, and CD16-mediated cell adhesion. |
| title_full_unstemmed | Quantification and modeling of tripartite CD2-, CD58FC chimera (alefacept)-, and CD16-mediated cell adhesion. |
| title_short | Quantification and modeling of tripartite CD2-, CD58FC chimera (alefacept)-, and CD16-mediated cell adhesion. |
| title_sort | quantification and modeling of tripartite cd2 cd58fc chimera alefacept and cd16 mediated cell adhesion |
| work_keys_str_mv | AT dustinm quantificationandmodelingoftripartitecd2cd58fcchimeraalefaceptandcd16mediatedcelladhesion AT starrt quantificationandmodelingoftripartitecd2cd58fcchimeraalefaceptandcd16mediatedcelladhesion AT coombsd quantificationandmodelingoftripartitecd2cd58fcchimeraalefaceptandcd16mediatedcelladhesion AT majeaug quantificationandmodelingoftripartitecd2cd58fcchimeraalefaceptandcd16mediatedcelladhesion AT meierw quantificationandmodelingoftripartitecd2cd58fcchimeraalefaceptandcd16mediatedcelladhesion AT hochmanp quantificationandmodelingoftripartitecd2cd58fcchimeraalefaceptandcd16mediatedcelladhesion AT douglassa quantificationandmodelingoftripartitecd2cd58fcchimeraalefaceptandcd16mediatedcelladhesion AT valer quantificationandmodelingoftripartitecd2cd58fcchimeraalefaceptandcd16mediatedcelladhesion AT goldsteinb quantificationandmodelingoftripartitecd2cd58fcchimeraalefaceptandcd16mediatedcelladhesion AT whittya quantificationandmodelingoftripartitecd2cd58fcchimeraalefaceptandcd16mediatedcelladhesion |